Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer (LEAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01411319
Recruitment Status : Completed
First Posted : August 8, 2011
Results First Posted : June 16, 2021
Last Update Posted : July 13, 2021
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alan Pollack, MD, PhD, University of Miami

Brief Summary:

The hypotheses of this study are:

  1. Delivery of single fraction Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) to the dominant tumor lesion(s) in the prostate as identified by multiparametric functional Magnetic Resonance Imaging is safe and feasible when given prior to standard prostate radiotherapy.
  2. Biomarker expression levels differ in the functional MRI identified suspicious tumor regions and unsuspicious tumor regions. The investigators hypothesize that a significant source of variation in biomarker levels is due to tumor heterogeneity and that it is molecular abnormalities in the dominant tumor areas that are angiogenic and determine outcome.

Condition or disease Intervention/treatment Phase
Prostate Cancer Prostate Adenocarcinoma Radiation: Lattice Extreme Ablative Dose Radiation Therapy Radiation: Standard IMRT Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
Actual Study Start Date : December 27, 2011
Actual Primary Completion Date : December 31, 2014
Actual Study Completion Date : March 2, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: LEAD Radiation Therapy
Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
Radiation: Lattice Extreme Ablative Dose Radiation Therapy
12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
Other Name: LEAD RT

Radiation: Standard IMRT
76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
Other Name: IMRT




Primary Outcome Measures :
  1. Number of Study Participants Experiencing Treatment-Related Toxicity [ Time Frame: Up to 8.5 weeks ]
    Toxicity are any Grade 2 or higher treatment-related adverse events as assessed by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0.

  2. Percentage of Enrolled Patients for Whom LEAD RT Dose Can be Successfully Administered Following MRI-guided Planning. [ Time Frame: Up to 8 weeks ]
    The percentage of enrolled patients for whom LEAD RT dose can be successfully administered following MRI-guided planning.


Secondary Outcome Measures :
  1. Number of Participants With Remaining Tumor Cells in the Prostate Post Treatment [ Time Frame: Up to 2.5 Years ]
    The number of participants with positive tumor cells left in the prostate after LEAD RT as evaluated by prostate biopsy.

  2. Percentage of Participants With Positive Prostate Biopsies After Completion of Treatment [ Time Frame: From Baseline to 2.5 Years Post Completion of Study Therapy (Approximately 3 years) ]
    Preliminary indication of efficacy of treatment will be reported as the percentage of participants with positive prostate biopsies after completion of treatment.

  3. Rate of Participants That Achieve Failure-Free Survival (FFS) [ Time Frame: Up to 6 years ]
    The percentage of participants achieving FFS will be reported. Failure-free is defined as no documented evidence of biochemical and/or or clinical failure or death from any cause, whichever occur first. Biochemical failure is defined is a increase of 2 or greater from nadir of Prostate Specific Antigen (PSA) levels. Clinical Failure is defined as newly identified extension outside the prostate after initial regression, or urinary obstructive symptoms with carcinoma or regional/distant failure due to radiographic evidence metastasis.

  4. Overall Survival (OS) [ Time Frame: Up to 6 years ]
    Overall survival is defined as the elapsed time from study enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact.

  5. HrQoL as Assessed by EPIC-SF12 Questionnaire [ Time Frame: At Baseline (Prior to RT), at 8 weeks (Last week of RT), At 6 weeks post RT, At 3 months post RT, At 6 months post RT, At 9 months post RT, At 15 months post RT, At 27 months post RT, At 39 months post RT, At 51 months post RT, At 63 months post RT ]
    Health-related Quality of Life (HRQOL) will be measured using the Expanded Prostate Cancer Index Composite and Medical Outcomes Study SF-12 (EPIC SF-12) to evaluate patient function and satisfaction after prostate cancer treatment. The questionnaire has 5 subscales (Urinary Function, Urinary Symptoms, Bowel Habits, Sexual Function and Hormonal Function). Each subscale has a total score ranging from 0-100, with higher scores representing better HRQOL.

  6. HrQoL as Assessed by MAX-PC Questionnaire [ Time Frame: At Baseline (Prior to RT), at 8 weeks (Last week of RT), At 6 weeks post RT, At 3 months post RT, At 6 months post RT, At 9 months post RT, At 15 months post RT, At 27 months post RT, At 39 months post RT, At 51 months post RT, At 63 months post RT ]
    Health-related quality of life (HRQOL) will be measured using the scores on the Modified 18-item Memorial Anxiety Scale for Prostate Cancer (MAX-PC) from pre-treatment to post-treatment. The scale consists of 18 items (e.g. "I thought about prostate cancer even though I didn't mean to.") scored on a scale from 0 ("not at all") to 3 ("often"). Total scores range from 0 to 54, with higher scores indicating higher levels of anxiety.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Biopsy confirmed adenocarcinoma of the prostate.
  2. T1-T3a disease based on digital rectal exam (DRE).

    • T3a disease based on MRI is acceptable (no evidence of frank (clear cut) seminal vesicle (SV) involvement or invasion of bladder or rectum).
  3. Gleason score 6-10.
  4. Patients with Gleason score ≥8 must be offered long term androgen deprivation therapy (ADT) and refuse such treatment because only 4-6 months (+/- 2 months) (short term ADT) is permitted (not required) on this protocol. The ADT is recommended to begin after fiducial marker placement; however, ADT is permitted to have been started up to two months prior to the signing of consent. All patients in this protocol may (not required) be treated with 4-6 months (+/- 2 months) of ADT, at the discretion of the treating physician.

    • Gleason ≥ 8 must have < 40% of the tissue involved with Gleason 8 in the biopsy specimen.
  5. Prostate-specific antigen (PSA) ≤ 30 ng/mL within 3 months of enrollment. If PSA was above 30 and dropped to ≤ 30 with antibiotics, this is acceptable for enrollment.
  6. No previous pelvic radiotherapy.
  7. No previous history of radical/total prostatectomy (suprapubic prostatectomy is acceptable).
  8. No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for ≥ 5 years then the patient is eligible.
  9. Identifiable multiparametric-MRI tumor lesion or lesions, that total in volume < 33% of the prostate

    • Multiparametric MRI of prostate and pelvis is required prior to protocol consideration.
    • If contrast not given, the point dose on the apparent diffusion coefficient (ADC) map should be < 1000.
  10. Ability to understand and the willingness to sign a written informed consent document.
  11. Zubrod performance status < 2.
  12. Willingness to fill out quality of life forms.
  13. Bone scan negative if PSA > 15 ng/mL or Gleason ≥ 8 disease. A questionable bone scan is acceptable if other imaging tests are negative for metastasis.
  14. Serum testosterone is within 40% of normal assay limits (e.g., x=0.4*lower assay limit and x=.04*upper assay limit + upper assay limit), and taken within 4 months of enrollment. Patients who have been started on ADT prior to signing consent are not required to have a serum testosterone at this level prior to signing consent; but, a serum testosterone prior to fiducial marker placement is recommended.
  15. Serum liver function tests (LFT) are taken within 3 months of enrollment.
  16. Complete blood counts are taken within 3 months of enrollment.
  17. Age ≥ 35 and ≤ 85 years.

Exclusion Criteria:

  1. > T3a disease on digital rectal exam or >T3a disease clearly identified by MRI.
  2. Gleason score < 6.
  3. ≥ 40% Gleason 8-10 tumor, over the total tissue including other tumor and normal tissue. For example: (Gleason 8-10 tumor length/other biopsy tissue length)*100 = ≥ 40%.
  4. Androgen deprivation therapy longer than 8 months. Androgen deprivation timing is for the Luteinizing hormone-releasing hormone (LHRH) agonist portion only and not when anti-androgen is started beforehand with the purpose of counteracting the surge in testosterone from the LHRH agonist - PSA > 30 ng/mL within 3 months of enrollment.
  5. PSA > 30 ng/mL within 3 months of enrollment
  6. Unable to obtain a 1.5T or 3.0T multiparametric MRI of the pelvis and prostate with contrast.
  7. Unidentifiable multiparametric MRI tumor lesion.
  8. Identifiable multiparametric-MRI tumor lesions, that total in volume ≥ 33% of the prostate.
  9. Previous pelvic radiotherapy.
  10. Previous history of radical prostatectomy.
  11. Concurrent, active malignancy, which is not nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for < 5 years then the patient is not eligible.
  12. Zubrod performance status ≥ 2.
  13. Inability to understand or unwilling to sign a written informed consent document
  14. Unwilling to fill out quality of life/psychosocial forms.
  15. Bone scan is positive and other imaging tests confirm a suspicion of metastasis from prostate cancer.
  16. Serum testosterone is not within 40% of normal assay limits taken within 4 months of enrollment (only applicable to patients not started on ADT prior to signing consent).
  17. Serum liver function tests (LFTs) are not taken within 3 months of enrollment.
  18. Complete blood counts are not taken within 3 months of enrollment.
  19. Age < 35 and > 85 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01411319


Locations
Layout table for location information
United States, Florida
University of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Alan Pollack, MD, PhD University of Miami
  Study Documents (Full-Text)

Documents provided by Alan Pollack, MD, PhD, University of Miami:
Publications of Results:
Layout table for additonal information
Responsible Party: Alan Pollack, MD, PhD, Professor, University of Miami
ClinicalTrials.gov Identifier: NCT01411319    
Other Study ID Numbers: 20100389
R21CA153826 ( U.S. NIH Grant/Contract )
First Posted: August 8, 2011    Key Record Dates
Results First Posted: June 16, 2021
Last Update Posted: July 13, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases